Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

NCT ID: NCT07312292

Last Updated: 2025-12-31

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2027-11-01

Brief Summary

This clinical trial will test whether a short infusion of a drug called angiotensin II can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization.

The main questions it aims to answer are:

• Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver?
• Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do?
• First visit (work-up): Participants will have the standard preparation for radioembolization. A small test dose of radioactive tracer (99mTc-MAA) will be injected into the liver through an artery. On the same day, a SPECT/CT scan will be performed to see how the tracer distributes in the liver and if there are depositions outside the liver. If everything looks good, the participant will return for treatment in 2-3 weeks.
• Second visit (treatment): Participants will receive the actual radioembolization treatment. At each injection site in the liver, first angiotensin II is administered, immediately followed by the injection of the radioactive beads (90Y microspheres). If the treatment requires injections in multiple locations, the participant will receive angiotensin II at each spot.
• After treatment: Participants will receive a PET/CT scan so the research team can see where the radioactive beads went. This will be compared to the distribution of the radioactive tracer (99mTc-MAA) from the first SPECT/CT scan (performed without angiotensin II) to measure how much angiotensin II helped target the tumor.

All monitoring (including blood pressure, heart rate, oxygen saturation, and breathing rate) takes place during the procedure as part of routine care, and there are no extra hospital visits beyond what is normally required for radioembolization.

Conditions

Liver Cancer (Locally Advanced or Metastatic); Liver Cancer Adult

Keywords

Radioembolization; Angiotensin II; yttrium-90

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Radioembolization with intra-arterial angiotensin II

Single-arm study in which all participants undergo standard yttrium-90 (⁹⁰Y) radioembolization for primary or metastatic liver tumors. During the therapeutic radioembolization procedure, angiotensin II is administered intra-arterially immediately prior to ⁹⁰Y glass microsphere injection at each arterial injection position.

Group Type: EXPERIMENTAL

Angiotensin II (Giapreza®)

Intervention Type: DRUG

Angiotensin II is administered intra-arterially into the hepatic artery during the therapeutic radioembolization procedure. After confirmation of correct microcatheter position, angiotensin II is infused at a dose of 10 µg/min for 100 seconds, immediately followed by injection of yttrium-90 glass microspheres (TheraSphere®).

In participants with multiple arterial injection positions, angiotensin II is administered at each injection position. In cases where whole-liver treatment is performed in two separate sessions, angiotensin II is administered during both treatment sessions.

Dose: 10 µg/min Duration of Administration: 100 seconds per injection position Route of Administration: Intra-arterial (hepatic artery)

Yttrium-90 radioembolization

Intervention Type: RADIATION

Selective intra-arterial administration of yttrium-90 glass microspheres for the treatment of primary or metastatic liver tumors, performed according to standard clinical protocol.

Interventions

Angiotensin II (Giapreza®)

Angiotensin II is administered intra-arterially into the hepatic artery during the therapeutic radioembolization procedure. After confirmation of correct microcatheter position, angiotensin II is infused at a dose of 10 µg/min for 100 seconds, immediately followed by injection of yttrium-90 glass microspheres (TheraSphere®).

In participants with multiple arterial injection positions, angiotensin II is administered at each injection position. In cases where whole-liver treatment is performed in two separate sessions, angiotensin II is administered during both treatment sessions.

Dose: 10 µg/min Duration of Administration: 100 seconds per injection position Route of Administration: Intra-arterial (hepatic artery)

Intervention Type: DRUG

Yttrium-90 radioembolization

Selective intra-arterial administration of yttrium-90 glass microspheres for the treatment of primary or metastatic liver tumors, performed according to standard clinical protocol.

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Patients diagnosed with primary or metastatic liver tumors (any histological type).
• A clinical indication for radioembolization.
• Liver tumors with a diameter ≥ 2 cm.
• Age ≥ 18 years.
• Competent and able to provide own informed consent (no legally designated representative).
• Written informed consent.

Exclusion Criteria

• Any serious comorbidity preventing the safe administration of AT-II. This includes:

1. Uncontrolled hypertension.

2. Treatment with ≥ 3 antihypertensive drugs.

3. Arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months.

• Current use of angiotensin-converting enzyme (ACE) inhibitors.
• Current use of angiotensin II receptor blockers (ARBs).
• Known hypercoagulable state (i.e., thrombophilia).
• History of severe peripheral vascular disease.
• Known hypersensitivity to the active substance in Giapreza: angiotensin II.
• Known hypersensitivity to any of the excipients in Giapreza: mannitol, sodium hydroxide or hydrochloric acid.
• Any serious and/or chronic liver disease preventing the safe administration of radioembolization.
• Uncorrectable extrahepatic deposition of scout dose activity; activity in the falciform ligament, portal lymph nodes, and gallbladder is accepted.
• Pregnancy or breastfeeding.
• Body weight over 150 kg (because of maximum table load).
• Known severe allergy to intravenous contrast fluids.
• Participation in another investigational study which may compromise any endpoint of the study.
• Any other significant comorbidity or medical condition that may compromise the safety of radioembolization.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Niek Wijnen

OTHER

Sponsor Role: lead

PAION Deutschland GmbH

INDUSTRY

Sponsor Role: collaborator

Responsible Party

Niek Wijnen

MD

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

University Medical Center Utrecht

Utrecht, Utrecht, Netherlands

Countries

Netherlands

Central Contacts

Niek Wijnen, MD

Role: CONTACT

Phone: +31652022145

Email: n.wijnen-5@umcutrecht.nl

Facility Contacts

Niek Wijnen, MD

Role: primary

References

van den Hoven AF, Smits ML, Rosenbaum CE, Verkooijen HM, van den Bosch MA, Lam MG. The effect of intra-arterial angiotensin II on the hepatic tumor to non-tumor blood flow ratio for radioembolization: a systematic review. PLoS One. 2014 Jan 17;9(1):e86394. doi: 10.1371/journal.pone.0086394. eCollection 2014.

Reference Type: RESULT

PMID: 24466071 (View on PubMed)

Other Identifiers

2025-521870-33-00

Identifier Type: CTIS

Identifier Source: secondary_id

24U-0008

Identifier Type: -

Identifier Source: org_study_id